Res. Immunol. 
1992, 143, 145-148 
        
        Oxidative Stress, HIV and AIDS 
        
        
        E. Papadopulos-Eleopulos (1) V.F. Turner (2) and J.M. Papadimitriou 
        (3) 
        
        (1) Department of Medical Physics, (2) Emergency 
        Department and (3) Department of Pathology, (University of Western 
        Australia), Royal Perth Hospital, Wellington St., Perth 6001 (Western 
        Australia)
        
As long ago as 1983, one of us (E.P.-E.) proposed that 
        oxidative mechanisms are of critical significance in the genesis of AIDS 
        (acquired immune deficiency syndrome). A prediction of this hypothesis 
        was that the mechanisms responsible for AIDS could be reversed by the 
        administration of reducing agents, especially those containing 
        sulphydryl groups (SH groups). The discovery of HIV resulted in a 
        broadening of this hypothesis in that it considered oxidative stress as 
        a principal mechanism in both the development of AIDS and expression of 
        HIV (Papadopulos-Eleopulos, 1988; Papadopulos-Eleopulos et al., 1989). 
        However, the general acceptance of the HIV hypothesis of AIDS completely 
        overshadowed this alternative hypothesis, and although many other 
        scientists have questioned the role of HIV in the causation of AIDS 
        (Duesberg, 1987; Root-Bernstein, 1990) Robert Gallo and most AIDS 
        researchers consider HIV to be the sole "sine qua non" cause of AIDS. 
        
        Notwithstanding, some flaws, especially recently, have appeared which 
        cast serious doubt on the prevailing HIV/AIDS hypothesis. Luc 
        Montagnier, the discoverer of HIV, is presently of the opinion that 
        cofactors are necessary for the appearance of AIDS (Lemaitre et al., 
        1990). It has been accepted by researchers at the CDC that KS (Kaposi's 
        sarcoma), the first and most specific of the AIDS indicator diseases, 
        for which the explanation of the HIV hypothesis was put forward by Gallo 
        in 1982, is not caused directly or indirectly by HIV (Beral et al., 
        1990). On the other hand, recent empirical observations from three 
        seemingly unrelated areas of AIDS research are in agreement with the 
        hypothesis that oxidative mechanisms play a critical role in HIV 
        expression and AIDS development. 
        (1) Pompidou et al. (1985a) and more recently researchers from many 
        other institutions (Lang et al., 1988; Brewton et al., 1989; Reisinger 
        et al., 1990; Hersh et al., 1991) have shown that a reducing agent, 
        diethyl dithiocarbonate, previously used as an immunomodulator, and 
        inhibitor of tumour promotion, may be useful in improving the immune 
        response in HIV infected individuals and in preventing and treating 
        AIDS. Other reducing agents have also been found to have similar effects 
        (Schulof et al., 1986; Wu et al., 1989). 
        (2) In 1989, Eck et al. measured the level of acid soluble-SH groups 
        in plasma and the intracellular concentration of reduced glutathione 
        (GSH) in peripheral blood mononuclear cells (PBMC) and monocytes in 
        HIV-infected patients: both were found to be significantly decreased. 
        Following the above report, Buhl et al. (1989) determined the 
        glutathione concentration (reduced, oxidised and total) in plasma and 
        lung epithelial lining fluid of symptom-free HIV seropositive 
        individuals: in both tissues, both the reduced and total GSH 
        concentration was found to be significantly decreased. 
        (3) In 1985, Pompidou et al. (1985b) and more recently many other 
        researchers including Anthony Fauci have shown that reducing agents 
        suppress the expression of HIV (Scheib et al., 1987; Bitterlich et al., 
        1989; Kalebic et al., 1991).
        Because of the possible therapeutic implications of reducing agents 
        in AIDS patients it is important to have a basic understanding as to 
        why: 
        - reducing agents suppress the expression of HIV; 
        - asymptomatic HIV-infected individuals and AIDS patients have 
        decreased sulphydryl and total glutathione levels.
        HIV expression and reducing agents
        The answer to the first question is encompassed in basic retroviral 
        research conducted over half a century. It is well known that all cells 
        contain retroviral genomic sequences (Martin et al., 1981 ; Callahan et 
        al., 1989; Nakamura et al., 1991). Recently French researchers suggested 
        that human DNA also contains sequences which are homologous with the HIV 
        genome (Parravicini et al., 1988). Many eminent retrovirologists, 
        including Weiss, did not exclude the possibility that retroviruses with 
        gene sequences not originally present in cells may arise during the 
        lifetime of the animal by duplication and/or recombination of endogenous 
        proviruses or even by rearrangement of cellular DNA, caused by many 
        factors including the pathogenic process itself, and that retroviruses 
        may be the effect and not the cause of the disease (Weiss et al., 1971). 
        
        According to Temin (1974) who shared the Nobel prize with Baltimore 
        for the discovery of reverse transcriptase (RT) and who, from the time 
        of its discovery considered the enzyme to be constituent of all cells 
        not just retroviruses, the genome of a retrovirus (ribodeoxyvirus) may 
        arise by rearrangement of the normal cell genome by the following 
        mechanism. "A section of a cell genome becomes modified in successive 
        DNA(w) to RNA(-) to DNA transfers until it becomes a ribodeoxyvirus 
        genome. First, these sequences evolve as part of a cellular genome. 
        After they have escaped as a virus they evolve independently as a virus 
        genome. The time may be millions of years in germ-line cells and days in 
        somatic cells". In fact, Temin and Baltimore (1972) did not exclude the 
        possibility that, in at least some cases, particles which band at 1. 16 
        g/ml contain RT and have morphological characteristics similar to 
        retroviruses, may be nothing more than cellular fragments. Irrespective 
        of the mechanism it is a fact, firmly established from basic retroviral 
        research, that retroviruses can appear even in virus-free cultures with 
        a rate that can be accelerated a million-fold by radiation, infection 
        with other viruses and mitogens (Weiss et al., 1971 Aaronson et al., 
        1971). 
        Of particular relevance to the present discussion is the fact that 
        all mitogenic agents including radiation exert their biological effect 
        by oxidation of cellular sulphydryl groups (Papadopulos-Eleopulos, 
        1982). 
        Montagnier and his associate David Klatzmann were the first to draw 
        attention to the fact that LAV infection of T4 cells in vitro does not 
        lead to HIV expression unless the cells are stimulated. "Infection of 
        resting T4 cells does not lead to viral replication or to expression of 
        viral antigens on the cell surface, while stimulation by lectins or 
        antigens of the same cells results in production of viral particles, 
        antigenic expression and the cytopathic effect" (Klatzmann and 
        Montagnier, 1986). Gallo also expressed the view that without 
        "activation" the T4 cells do not express virus (Zagury et al., 1986). 
        But, apparently, they did not realise that oxidative phenomena are 
        implicated in human T-cell stimulation (Sekkat et al., 1988). 
        As early as 1984 it was realised that in vivo HIV genomic sequences 
        are not always detected in tissues obtained from patients with ARC and 
        AIDS or, when found, the "signal" is low. According to Gallo and his 
        colleagues "this low signal intensity could also be explained by the 
        presence of a virus distantly homologous to HTLV-III in these cells" 
        (Shaw et al., 1984). 
        Anthony Fauci and his colleagues, on comparing the evidence obtained 
        from the study of macrophages in vivo and in vitro, concluded: "These 
        data indicate that the ability to isolate in vitro macrophage tropic 
        strains of HIV does not reflect in vivo infection of circulating 
        monocytes, but is related to phenomena of in vitro selection or 
        adaptation" (Massari et al., 1990). 
        Furthermore, (a) to date, with perhaps one exception, no two 
        identical HIV have been isolated, not even from the same person; in one 
        case where two sequential isolates were made 16 months apart, none of 
        the provirus in the first isolate was found in the second (Saag et al., 
        1988); (b) the genetic data obtained in vitro does not correlate with 
        the data obtained in vivo - "To culture is to disturb" (Meyerhans et 
        al., 1989); (c) many, if not all, of the proviruses detected in vivo and 
        in vitro are defective. 
        This data led researchers at the Pasteur Institute and their 
        associates to conclude that (1) "the task of defining HIV infection in 
        molecular terms will be difficult", (2) "virus isolated from PBMC may be 
        produced by the complementation of defective genes or by recombination 
        between two of them" (Meyerhans et al., 1989; Wain-Hobson, 1989). Be 
        this as it may, of particular relevance to the present discussion is the 
        fact that: 
        a) HIV has been isolated only from in vitro cultures; 
        b) no HIV can be isolated, unless the cultures, one way or the other, 
        are subjected to oxidative stress, even although the tissue from AIDS 
        patients is already oxidised; it may be then that oxidative stress is of 
        pivotal significance in the detection of all retroviruses including HIV. 
        If oxidation is a prerequisite for HIV expression, it follows that 
        reducing agents will have the opposite effect: HIV will not be expressed 
        in their presence. 
        Oxidative factors in AIDS patients 
        AIDS patients suffer from many opportunistic microorganisms. Like all 
        cells, these microorganisms require reducing equivalents, including SH, 
        for division and survival (Papadopulos-Eleopulos, 1982) which they 
        obtain to the detriment of body tissues. In AIDS patients, a decrease in 
        the level of SH may also result from malnutrition and diarrhoea. 
        However, opportunistic infections, diarrhoea and malnutrition cannot 
        account for the low level of GSH and acid-soluble SH found in 
        HIV-positive, symptom-free, well-nourished homosexuals and 
        haemophiliacs. 
        Since viral production also requires thiols, which they obtain from 
        the host, it may be reasonable to assume that the decreased SH level in 
        HIV-positive individuals may be the result of HIV infection, as has 
        already been proposed for SIV-infected monkeys (Eck et al., 1991). 
        However, because for both HIV and SIV expression, oxidative stress is a 
        prerequisite, this cannot be the case, i.e. oxidation cannot be both the 
        cause and the effect of HIV expression (Papadopulos-Eleopulos et al., 
        1991). 
        At first sight it appears that there is no common factor, apart from 
        HIV infection, linking the various AIDS risk groups. However, 
        homosexuals are exposed to relatively high levels of nitrites and anally 
        deposited sperm, drug abusers to opiates and nitrites, haemophiliacs to 
        factor VIII. All these are known potent oxidising agents which oxidise 
        many cellular reducing equivalents such as NADPH and all sulphydryl 
        groups, including those of cysteine (acid-soluble thiols) 
        (Papadopulos-Eleopulos, 1988). 
        In normal tissue almost all glutathione is found intracellularly in 
        the reduced form (GSH) where it is also synthesised from glutamic acid, 
        cysteine and glycine, in the presence of ATP and magnesium. Cysteine 
        which is the rate-limiting amino acid cannot be substituted by its 
        oxidised form, cystine. Oxidation of cysteine (acid-soluble SH) is also 
        known to decrease cellular ATP and magnesium concentration (Tateishi and 
        Higashi, 1978; Siliprandi et al., 1987). Malnutrition and diarrhoea may 
        also lead to cysteine, magnesium and ATP deficiency. 
        As a result of the decrease in cysteine, ATP and magnesium 
        concentration, the synthesis of glutathione will be inhibited. The 
        oxidising agents to which the AIDS risk groups are exposed would also 
        directly oxidise GSH to GSSG. GSSG is efficiently excreted from cells 
        (Sies and Akerbrum, 1984). Glutathione exported across the cell membrane 
        interacts with gamma-glutamyl transpeptidase, an enzyme which catalyses 
        the breakdown of glutathione by transferring the gamma-glutamyl group to 
        an acceptor. 
        It should be noted that: cystine is one of the best acceptors for the 
        gamma-glutamyl group; with exception of the kidney and pancreas, the 
        highest activity of the enzyme is in the epididymis and seminal 
        vesicles; the highest concentration of its soluble form, apart from 
        urine and pancreatic juice, is in seminal fluid (Meister and Anderson, 
        1983). Thus, the systemic decrease of glutathione concentration in HIV 
        seropositive individuals may result from both, decrease in synthesis and 
        increased degradation. The oxidative stress to which the AIDS patients 
        are subjected would lead to cellular anomalies in many cells, including 
        lymphocytes, resulting in opportunistic infection, immunological 
        abnormalities and neoplasia. 
        All this argues in favour of oxidation as being a critical factor in 
        the pathogenesis of AIDS and HIV expression.
        References 
        Aaronson, S.A., Todaro, G.J. & Scolnick, E.M. 
        (1971), Induction of murine C-type viruses from clonal lines of 
        virus-free BALB/3T3 cells. Science, 174, 157-159. 
        Beral, V., Peterman, T. A., Berkelman, R. L. et al. 
        (1990), Kaposi's sarcoma among persons with AIDS: a sexually transmitted 
        infection? Lancet, 1, 123-128. 
        Bitterlich, G., Larcher, C., Solder, B. et al. (1989), 
        Effect of D-penicillamine on the expression and propagation of the human 
        immunodeficiency virus by H9 T-lymphoblastoid cells. Drug Res., 39 
        (II).Nr 7, 824-828. 
        Brewton, G.W., Hersh, E.M., Rios, A. et al. (1989), A 
        pilot study of diethyldithiocarbamate in patients with acquired immune 
        deficiency syndrome (AIDS) and the AIDS-related complex. Life Sci., 45, 
        2509-2520. 
        Buhl, R., Holroyd, K. J., Mastrangell, A. et al. 
        (1989), Systemic glutathione deficiency in symptom-free-HIV seropositive 
        individuals. Lancet, 11, 1294-1297. 
        Callahan, R., Chiu, I., Wong, J.F.H. et al. (1985), A 
        new class of endogenous human retroviral genomes. Science, 288, 
        1208-1211. 
        Deusberg, P.H. (1987), Retroviruses as carcinogens and 
        pathogens: expectations and reality. Cancer Res., 47, 1199-1220. 
        
        Eck, H.P., Stahl-Hennig, C., Hunsmann, G. et al. 
        (1991), Metabolic disorder of early consequence of simian 
        imniunodeficiency virus infection in rhesus macaques. Lancet, 1, 
        346-347. 
        Eck, H.P., Gmunder, H., Hartmann, M. et al. (1989), Low 
        concentrations of acid soluble thiol (cysteine) in the blood plasma of 
        HIV-1-infected patients. Biol. Chem. Hoppe-Selyer, 370, 101-108. 
        
        Hersh, E.M., Brewtom, G., Abrams, D. et al. (1991), 
        Ditiocarb sodium (diethyldithiocarbamate) therapy in patients with 
        symptomatic HIV infection and AIDS. J. Amer. med. Ass., 265, 1538-1544. 
        
        Katebic, T., Kinter, A., Poli, G. et al. (1991), 
        Suppression of human immunodeficiency virus expression in chronically 
        infected monocytic cells by glutathione, glutathione ester, and 
        N-acetylcysteine. Proc. nat. Acad. Sci. (Wash.), 88, 986-990. 
        Klatzmann, D. & Montagnier, L. (1986), Approaches 
        to AIDS therapy. Immunology, 319, 10-11. 
        Lang, J.M., Touraine, J.L. & Tr‚po, C. (1988), 
        Randomised, double-blind placebo-controlled trial of ditiocarb sodium 
        ("Imuthiol") in human immunodeficiency virus infection. Lancet, II, 
        702-706. 
        Lemaitre, M., Gu‚tard, D., H‚nin, Y. et al. (1990), 
        Protective activity of tetracyline analogs against the cytopathic effect 
        of the human immunodeficiency viruses in CEM cells. Res. Virol., 141, 
        5-16. 
        Martin, M.A., Bryan, T., Rasheed, S. et al. (1981), 
        Identification and cloning of endogenous retroviral sequences present in 
        human DNA. Proc. nat. Acad. Sci. (Wash.), 78, 4892-4896. 
        Massari, F.E., Poli, G. & Schnittman, S.M. (1990), 
        In vivo T-lymphocyte origin of macrophage-trophic strains of HIV. J. 
        Immunol., 144, 4628-4632. 
        Mcister, A. & Anderson, M.E. (1983), Glutathione. 
        Ann. Rev. Biochem., 52, 711-760. 
        Meyerhans, A., Cheynier, R., Albert, J. et al. (1989), 
        Temporal fluctuations in HIV quasispecies in vivo are not reflected by 
        sequential HIV isolations. Cell, 58, 901-910. 
        Nakamura, N., Sugino, H., Takahara, K. et al. (1991), 
        Endogenous retroviral LTR DNA sequences as markers for individual human 
        chromosomes. Cytogenet. Cell. Genetics, 57, 18-22. 
        Papadopulos-Eleopulos, E., Hedland-Thomas, B., Causer, 
        D.A. et al. (1989), An alternative explanation for the 
        radiosensitization of AIDS patients. Int. J. Radiat. Oncol. Biol. Phys., 
        17, 695-696. 
        Papadopulos-Eleopulos, E. (1982), A mitotic theory. J. 
        theor. Biol., 96, 741-758. 
        Papadopulos-Eleopulos, E. (1988), Reappraisal of AIDS. 
        Is the oxidation induced by the risk factors the primary cause? Med. 
        Hypotheses, 25, 151-162. 
        Papadopulos-Eleopulos, E., Hedland-Thomas, B., Causer, 
        D.et al. (1991), Changes in thiols and glutamate as consequences of 
        simian immunodeficiency virus infection. Lancet, 11, 1013. 
        Parravicini, C.I,., Klatzmann, D., Jaffray, P. et al. 
        (1988), Monoclonal antibodies to the human immunodeficiency virus p18 
        protein cross-react with normal human tissues. AIDS, 2, 171-177. 
        
        Pompidou, A., Delsaux, M.C., Telvi, L. et al. (1985a), 
        Isoprinosine and imuthiol, two potentially active compounds in patients 
        with AIDS-related complex symptoms. Cancer Res. (Suppl.), 45, 
        4671s-4673s. 
        Pompidou, A., Zagury, D., Gallo, R.C. et al. (1985b), 
        In vitro inhibition of LAV/HTLV-III-infected lymphocytes by dithiocarb 
        and inodine pranobex. Lancet, II, 1423. 
        Reisinger, E.C., Kern, P., Ernest, M. et al. (1990), 
        Inhibition of HIV progression by dithiocarb. Lancet, 335, 679-682. 
        
        Root-Bernstein, R.S. (1990), Do we know the cause(s) of 
        AIDS? Perspect. Biol. Med., 33, 480-500. 
        Saag, M.S., Hahn, B.H., Gibbons, J. et al. (1988), 
        Extensive variation of human immunodeficiency virus type-1 in vivo. 
        Nature (Lond.), 334, 440-444. 
        Scheib, R.G., Parenti, D.M. & Simon, G.L. (1987), 
        Prolonged antiviral activity of D-penicillamine in human 
        immunodeficiency virus-infected homosexual. Men. Amer. J. Med., 83, 608. 
        
        Schulof, R.S., Scheib, R.G., Parenti, D.M. et al. 
        (1986), Treatment of HTLV-III/LAV-infected patients with 
        D-penicillamine. Drug Res. 36, (11),Nr 10, 1530-1535. 
        Sekkat, C., Dornand, J. & Gerber, M. (1988), 
        Oxidative phenomena are implicated in human T-cell stimulation. 
        Immunology, 63, 431-437. 
        Shaw, G.M., Hahn, B.H., Araya, S.K. et al. (1984), 
        Molecular characterization of human T-cell leukaemia (lymphotrophic) 
        virus type III in the acquired immune deficiency syndrome. Science, 226, 
        1165-1171. 
        Sies, H. & Akerbrum, T.P.M. (1984), Glutathione 
        disulfide (GSSG) efflux from cells and tissues. Methods Enzymol., 105, 
        445-451. 
        Siliprandi, N., Siliprandi, D., Bindoli, A. et al. 
        (1978), Effect of oxidation of glutathione and membrane thiol groups on 
        mitochondrial functions, in: Functions of glutathione in liver and 
        kidney (H. Sies & A. Wendel) (pp. 139-147). Springer-Verlag, 
        Heidelberg. 
        Tateishi, N. & Higashi, T. (1978), Turnover of 
        glutathione in rat liver, in "Functions of glutathione in liver and 
        kidney" (H. Sies & A. Wendel) (pp. 3-7). Springer Verlag, 
        Heidelberg. 
        Temin, H.M. & Baltimore, D. (1972), RNA-directed 
        DNA synthesis and RNA tumour viruses. Advanc. Virus Res., 17, 129-187. 
        
        Temin, H.W. (1974), On the origin of RNA tumour 
        viruses. Harvey Lect., 69, 173-197. 
        Wain-Hobson, S. (1989), HIV genome variability in vivo. 
        AIDS, 3, S13-SI8. 
        Weiss, R.A.Weiss, R. A., Friis, R. R., Katz, E. et al. 
        (1971), Induction of avian tumor viruses in normal cells by physical and 
        chemical carcinogens. Virology, 46, 920-938. 
        Wu, J., Levy, E.M. & Black, P. H. (1989), 
        2-Mercaptoethanol and n-acetylcysteine enhance T-cell colony formation 
        in AIDS and ARC. Clin. exp. Immunol., 77, 1-10. 
        Zagury, D.,Bernard, J., Leonard, R. et al. (1986), Long 
        term cultures of HTLV-III-infected cells: a model of cytopathology of 
        T-cell depiction in AIDS. Science, 231, 850-853.